Skip to main content
Fig. 5 | Journal for ImmunoTherapy of Cancer

Fig. 5

From: FLT PET/CT imaging of metastatic prostate cancer patients treated with pTVG-HP DNA vaccine and pembrolizumab

Fig. 5

a Thyroid SUVmean at baseline and after three months for all patients. Patients that experienced a thyroid related-adverse event of Gr2 or greater are shown in various colors to distinguish them from patients that did not experience a thyroid-related adverse event (black). b Receiver operating characteristic curve showing the value of thyroid SUVmean at baseline for predicting which patients will go on to experience a thyroid-related adverse event

Back to article page